1253-28-7 Usage
Description
GESTONORONE CAPROATE is a pro-drug of Gestonorone, a steroidal progestin derived from natural sources. It possesses various physiological effects and is known for its role in modulating the body's hormonal balance. GESTONORONE CAPROATE has been demonstrated to accelerate body weight gain and induce atrophy of the prostate, uterus, and seminal vesicles in rats. Additionally, it functions as an inhibitor of the reductive pathway of Testosterone metabolism.
Uses
Used in Pharmaceutical Industry:
GESTONORONE CAPROATE is used as a hormonal agent for regulating the body's hormonal balance and treating conditions related to hormonal imbalances. Its ability to induce atrophy of certain reproductive organs and inhibit Testosterone metabolism makes it a potential candidate for various therapeutic applications.
Used in Research and Development:
GESTONORONE CAPROATE is used as a research compound for studying the effects of steroidal progestins on the body's hormonal balance and reproductive system. Its role in accelerating body weight gain and modulating Testosterone metabolism can provide valuable insights into the development of new drugs and therapies for various medical conditions.
Used in Veterinary Medicine:
GESTONORONE CAPROATE is used as a veterinary drug for managing hormonal imbalances and reproductive issues in animals. Its effects on body weight gain and atrophy of reproductive organs can be beneficial in treating specific conditions in veterinary patients.
Originator
Depostat,Schering AG
Manufacturing Process
2 Methods of producing of 17-α-hydroxyl-19-norprogesteron-17-capronate:
1. To a solution of 1.0 g 17-α-hydroxy-19-norprogesteron in 32 ml capronic
acid anhydride 1.32 g p-toluesulfonate (1 mole hydrate) were added, and
allowed to stand for 3 h at 37°C. To the solution 1.43 ml conc. hydrochloric
acid in 143 ml methanol were added and all this also for 1 h was left under
N2. Then mixture was washed with water and treated with ether. Ether extract
was washed with water, and dried with Na2SO4. After that ether was distilled
and residue was recrystallised with isopropyl ether. 1.1 g of 17-α-hydroxyl-19-
norprogesteron-17-capronate was obtained, melting point 123°-124°C.
2. 2.0 g 3-methoxy-17α-hydroxy-17β-acetyl-δ2,5(10)-oestradien, 60 ml
capronic acid anhydride, 2.6 g p-toluensulfonate and 18.0 g water were mixed
and left for 6 h at room temperature. Then solution obtained was treated
ether and sodium bicarbonate and washed with water. Etheral solution was
dried over sodium sulfate. After distillation of ether 3.1 g 3,17α-dihydroxy-
δ3,5-19-norpregnadien-3,17-dicapronate was produced.To solution of 3.1 g 3,17α-dihydroxy-δ3,5-19-norpregnadien-3,17-dicapronate
in 250 ml methanol 2.5 g conc. hydrochloric acid were added and mixture was
left for 1 h. Then mixture was filtered and residue was washed. After
recrystallisation with isopropyl ether 17-α-hydroxyl-19-norprogesteron-17-
capronate was obtained, melting point 121°-123°C.
Therapeutic Function
Progestin
Check Digit Verification of cas no
The CAS Registry Mumber 1253-28-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,2,5 and 3 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1253-28:
(6*1)+(5*2)+(4*5)+(3*3)+(2*2)+(1*8)=57
57 % 10 = 7
So 1253-28-7 is a valid CAS Registry Number.
InChI:InChI=1/C26H38O4/c1-4-5-6-7-24(29)30-26(17(2)27)15-13-23-22-10-8-18-16-19(28)9-11-20(18)21(22)12-14-25(23,26)3/h16,20-23H,4-15H2,1-3H3/t20-,21+,22+,23-,25-,26-/m0/s1
